title: Cellular immunotherapy for high-grade glioma.
abstract: The outcome for patients with the most common primary brain tumor, glioblastoma multiforme (GBM), remains poor. Several immunotherapeutic approaches are actively being pursued including antibodies and cell-based therapies. While the blood-brain barrier protects brain tumor cells from therapeutic antibodies, immune cells have the ability to traverse the blood-brain barrier and migrate into GBM tumors to exert their therapeutic function. Results of Phase I clinical studies with vaccines to induce GBM-specific T cells are encouraging and Phase II clinical trials are in progress. Nonvaccine-based cell therapy for GBM has been actively explored over the last four decades. Here we will review past clinical experience with adoptive cell therapies for GBM and summarize current strategies on how to improve these approaches.
authors.affiliation: Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. smg@bcm.edu
authors.forename: K H
authors.initials: KH
authors.lastname: Chow
authors.forename: Stephen
authors.initials: S
authors.lastname: Gottschalk
mesh_terms: D000951:Antigens, Neoplasm / Q000737:chemistry* / Q000276:immunology*; D002986:Clinical Trials as Topic; D005910:Glioma / Q000276:immunology / Q000628:therapy; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods* / Q000639:trends; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D016693:Receptors, Antigen, T-Cell, alpha-beta